PubMed Health⌕ Search

Biomedical subjects

T Durrigl

Publications and source records attributed to T Durrigl.

5 recordsLinked to original sources
PubMed1996

The prognosis of rheumatoid arthritis.

Sixty patients with early diagnosed rheumatoid arthritis according ARA criteria were followed up for 6.6 years with the goal to determine prognosis. The parameters relevant to patient and physician were selected for follow up. Radiological and functional deterioration was evident after 6.6 years in 3/4 of patients and there was no one of them to satisfy remission criteria. The most unfavourable predictor of final outcome was the degree of functional incapacity in early stage of rheumatoid arthritis. Second important predictor of poor prognosis was degree of radiological destructive changes especially on feet. Poor prognosis could be expected in patients with previous attacks and the beginning of disease in elderly age. General symptoms and affection of mesomelic joints can be also undesirable predictor. Sex, morning stiffness, joint pattern, laboratory findings and rheumatoid factor were not significant predictors for prognosis but they could influence certain variables of global assessment.

Adult↗
PubMed1984

Double-blind crossover comparison of piroxicam and indomethacin in rheumatoid arthritis.

This 10-week, double-blind, crossover study compared piroxicam (20 mg administered once daily) and indomethacin (25 mg administered three times daily) in patients with rheumatoid arthritis. In the 30 patients evaluated, both drugs produced statistically significant improvement after 4 weeks compared to placebo in all parameters measured with the exception of joint swelling and 10 m walking time. Piroxicam provided greater improvement with respect to the severity of pain, joint tenderness and restoration of motion, and was significantly more effective than indomethacin in reducing the consumption of paracetamol and in improving morning stiffness. Both drugs were equally effective in improving the remaining parameters measured. Roughly, two-thirds of the patients considered piroxicam to be the more effective agent. With both drugs side effects were mild and infrequent.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed1983

Double-blind crossover comparison of piroxicam and indomethacin in rheumatoid arthritis.

This 10-week, double-blind, crossover study compared piroxicam (20 mg given once daily) and indomethacin (25 mg given three times daily) in patients with rheumatoid arthritis. In the 30 patients evaluated, both drugs produced statistically significant improvement after 4 weeks compared to placebo in all measured parameters with the exception of joint swelling and 10 m walking time. Piroxicam tended to provide greater improvement in the severity of pain and joint tenderness than indomethacin, while both drugs were equally effective in improving morning stiffness, grip strength, and range of joint motion, and in decreasing paracetamol consumption. Nevertheless, roughly two-thirds of the patients considered piroxicam to be the more effective agent. With both drugs side effects were mild and infrequent.

Adolescent↗